(PharmaNewsWire.Com, July 03, 2019 ) According to research report Cancer Immunotherapy Market is expected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Cancer Immunotherapy market along with the estimates and forecasts of the revenue and market share analysis. Read More: https://www.marketsandmarkets.com/PressReleases/cancer-immunotherapy.asp Cancer immunotherapy drugs are designed to alter or boost the body’s natural immune response to fight cancer this market is research-driven with a high degree of dependence on the discovery of molecules that can generate an immune response against various indications. The cancer immunotherapy market has been segmented, on the basis of product into monoclonal antibodies, immunomodulators, vaccines, and check point inhibitors. The check point inhibitors segment is estimated to witness the highest CAGR during 2016-2021. The high growth can be attributed to the benefits offered by this therapeutic drug. The monoclonal antibody segment is expected to lead the global cancer immunotherapy market during the forecast period Monoclonal antibodies are emerging as the most effective therapeutic agents for the treatment of malignancy. They are currently one of the largest classes of agents approved for the treatment of cancer. Several antibodies are widely adopted, owing to their lesser side effects as compared to chemotherapy. Antibodies are developed to treat several cancers such as lymphoma, leukemia, melanoma, breast cancer, and lung cancer. Cancer monoclonal antibodies are sub-segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894 North America is expected to account for the largest share of the market during the forecast period Based on regions, the global Cancer Immunotherapy market is segmented into North America, APAC, Europe and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as increase in patient pool, and initiative taken by the government for the development of Cancer Immunotherapy. Key players in the Cancer Immunotherapy market include Amgen (US), AstraZeneca (UK), F.Hoffman La Roche (Switzerland), BayerAG (Germany), Bristol-myers squibb(US), Eli Lilly and Company (US), Janssen Global Services, LLC (Belgium), Merck (US), Novartis (Switzerland), Pfizer (US)
Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: 1-888-600-6441 newsletter@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
